Skip to main content

Articles

Page 1 of 59

  1. Although good treatment options exist for many headache disorders, not all patients benefit and disability continues to be large. To design strategies for improving headache care, real-world data observing sta...

    Authors: Ruth Ruscheweyh, Theresa Klonowki, Gudrun Goßrau, Torsten Kraya, Charly Gaul, Andreas Straube, Tim Patrick Jürgens, Jörg Scheidt and Stefanie Förderreuther
    Citation: The Journal of Headache and Pain 2022 23:74
  2. Growing evidence supports the important role of persistent sodium currents (INaP) in the neuronal excitability of various central neurons. However, the role of tetrodotoxin-resistant (TTX-R) Na+ channel-mediated ...

    Authors: Michiko Nakamura and Il-Sung Jang
    Citation: The Journal of Headache and Pain 2022 23:73
  3. Nucleus accumbens (NAcc) played an important role in pain mediation, and presents changes of neuronal plasticity and functional connectivity. However, less is known about altered perfusion of NAcc in chronic m...

    Authors: Mengqi Liu, Yijie Sun, Xin Li and Zhiye Chen
    Citation: The Journal of Headache and Pain 2022 23:72
  4. Gut microbial dysbiosis and gut-brain axis dysfunction have been implicated in the pathophysiology of migraine. However, it is unclear whether migraine-related cephalic allodynia could induce the alteration of...

    Authors: Shuai Miao, Wenjing Tang, Heng Li, Bozhi Li, Chunxiao Yang, Wei Xie, Tao Wang, Wenhao Bai, Zihua Gong, Zhao Dong and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2022 23:71
  5. Migraine is a chronic disease characterized by episodic headache attacks. No recent studies have, however been conducted on the epidemiology of migraine or the treatment landscape in Japan. This study was cond...

    Authors: Fumihiko Sakai, Koichi Hirata, Hisaka Igarashi, Takao Takeshima, Takeo Nakayama, Hiromi Sano, Hiroyuki Kondo, Yoshiyuki Shibasaki and Nobuyuki Koga
    Citation: The Journal of Headache and Pain 2022 23:70
  6. Clinical trials have demonstrated galcanezumab as safe and effective in migraine prevention. However, real-life data are still lacking and overlook the impact of galcanezumab on those different migraine facets...

    Authors: Marcello Silvestro, Alessandro Tessitore, Ilaria Orologio, Rosa De Micco, Lorenzo Tartaglione, Francesca Trojsi, Gioacchino Tedeschi and Antonio Russo
    Citation: The Journal of Headache and Pain 2022 23:69
  7. A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized contr...

    Authors: Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, Lars Bendtsen, Christina I. Deligianni, Raquel Gil-Gouveia, Zaza Katsarava, Antoinette MaassenVanDenBrink, Paolo Martelletti, Dimos-Dimitrios Mitsikostas, Raffaele Ornello, Uwe Reuter, Margarita Sanchez-del-Rio, Alexandra J. Sinclair, Gisela Terwindt, Derya Uluduz…
    Citation: The Journal of Headache and Pain 2022 23:67
  8. In this editorial we aim to provide an overview of Narrative-based Medicine (NBM) and highlight what it may offer to the care of individuals with headache disorders.

    Authors: Christian Lampl, Simona Sacco and Paolo Martelletti
    Citation: The Journal of Headache and Pain 2022 23:66
  9. The debilitating nature of migraine attacks is widely established; however, less is known about how the interictal burden (i.e., how patients are affected in-between migraine episodes) of migraine impacts on p...

    Authors: Siu Hing Lo, Katy Gallop, Timothy Smith, Lauren Powell, Karissa Johnston, Lena T. Hubig, Emma Williams, Vladimir Coric, Linda Harris, Gilbert L’Italien and Andrew J. Lloyd
    Citation: The Journal of Headache and Pain 2022 23:65
  10. Authors: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi and Fabrizio Vernieri
    Citation: The Journal of Headache and Pain 2022 23:64

    The original article was published in The Journal of Headache and Pain 2022 23:46

  11. Initial evidence have shown the short-term efficacy of sTMS in the acute and preventive treatment of migraine. It is unknown whether this treatment approach in the long-term is effective and well tolerated in ...

    Authors: J.O. Lloyd, B. Hill, M. Murphy, A. Al-Kaisy, A. P. Andreou and G. Lambru
    Citation: The Journal of Headache and Pain 2022 23:63
  12. Despite the prevalence of concussions in young athletes, the impact of headaches on neurocognitive function at baseline is poorly understood. We analyze the effects of a history of headache treatment on baseli...

    Authors: Lily McCarthy, Theodore C. Hannah, Adam Y. Li, Alexander J. Schupper, Eugene Hrabarchuk, Roshini Kalagara, Muhammad Ali, Alex Gometz, Mark R. Lovell and Tanvir F. Choudhri
    Citation: The Journal of Headache and Pain 2022 23:62
  13. Clinical trials have shown that erenumab is effective and well-tolerated for the preventive treatment of chronic migraine. To extend the results from clinical trials, we assessed the real-world efficacy and sa...

    Authors: Christopher Kjaer Cullum, Thien Phu Do, Messoud Ashina, Lars Bendtsen, Sarah Sonja Hugger, Afrim Iljazi, Julia Gusatovic, Josefin Snellman, Cristina Lopez-Lopez, Håkan Ashina and Faisal Mohammad Amin
    Citation: The Journal of Headache and Pain 2022 23:61
  14. Several preclinical and clinical lines of evidence suggest a role of neuroinflammation in migraine. Neuroimaging offers the possibility to investigate and localize neuroinflammation in vivo in patients with migra...

    Authors: Rune Häckert Christensen, Cédric Gollion, Faisal Mohammad Amin, Michael A. Moskowitz, Nouchine Hadjikhani and Messoud Ashina
    Citation: The Journal of Headache and Pain 2022 23:60
  15. The clinical use of calcitonin gene-related peptide receptor (CGRP-R) antagonists and monoclonal antibodies against CGRP and CGRP-R has offered new treatment possibilities for migraine patients. CGRP activates...

    Authors: Sanne Hage La Cour, Kiki Juhler, Lisette J. A. Kogelman, Jes Olesen, Dan Arne Klærke, David Møbjerg Kristensen and Inger Jansen-Olesen
    Citation: The Journal of Headache and Pain 2022 23:59
  16. Cluster headache is a less-prevalent primary headache disorder but is overrepresented with regards to use of health care and social services. More insight into the socioeconomic impact is required.

    Authors: Anja Sofie Petersen, Nunu Lund, Agneta Snoer, Rigmor Højland Jensen and Mads Barloese
    Citation: The Journal of Headache and Pain 2022 23:58
  17. Authors: Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow and Christian Lampl
    Citation: The Journal of Headache and Pain 2022 23:57

    The original article was published in The Journal of Headache and Pain 2021 22:141

  18. Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy a...

    Authors: Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, Oscar Patterson-Lomba, Michael J. Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu and Rajeev Ayyagari
    Citation: The Journal of Headache and Pain 2022 23:56
  19. Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety and tolerabil...

    Authors: Hannah Schenk, Dagny Holle, Michael Nsaka, Christoph Kleinschnitz, Martin Glas and Armin Scheffler
    Citation: The Journal of Headache and Pain 2022 23:55
  20. Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patient...

    Authors: Lynda J. Krasenbaum, Vasantha L. Pedarla, Stephen F. Thompson, Krishna Tangirala, Joshua M. Cohen and Maurice T. Driessen
    Citation: The Journal of Headache and Pain 2022 23:54
  21. Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide (CGRP) pathway raised new hopes. CGRP, a potent vasodilator, plays a key ro...

    Authors: Alexandre O. Gérard, Diane Merino, Elise K. Van Obberghen, Fanny Rocher, Alexandre Destere, Michel Lantéri-Minet and Milou-Daniel Drici
    Citation: The Journal of Headache and Pain 2022 23:53
  22. The discovery of the prominent action of Calcitonin Gene Related Peptide –CGRP- on trigeminal afferents and meningeal vessels, opened a new era in migraine treatment. However, how the block of nociceptive affe...

    Authors: Marina de Tommaso, Marianna La Rocca, Silvia Giovanna Quitadamo, Katia Ricci, Giusy Tancredi, Livio Clemente, Eleonora Gentile, Elena Ammendola and Marianna Delussi
    Citation: The Journal of Headache and Pain 2022 23:52
  23. Authors: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi and Fabrizio Vernieri
    Citation: The Journal of Headache and Pain 2022 23:51

    The original article was published in The Journal of Headache and Pain 2022 23:46

  24. Triptans are the first-line option for the acute treatment of migraine attacks; however, triptans are contraindicated in people with certain underlying cardiovascular risk factors and are associated with inade...

    Authors: Richard B. Lipton, Rashmi B. Halker Singh, Dennis A. Revicki, Sihui Zhao, Anand R. Shewale, Jordan E. Lateiner and David W. Dodick
    Citation: The Journal of Headache and Pain 2022 23:50
  25. The Global Campaign against Headache, as a collaborative activity with the World Health Organization (WHO), was formally launched in Copenhagen in March 2004. In the month it turns 18, we review its activities...

    Authors: Timothy J. Steiner, Gretchen L. Birbeck, Rigmor H. Jensen, Paolo Martelletti, Lars Jacob Stovner, Derya Uluduz, Matilde Leonardi, Jes Olesen and Zaza Katsarava
    Citation: The Journal of Headache and Pain 2022 23:49
  26. Eptinezumab 100 mg and 300 mg met the primary efficacy endpoint in both PROMISE clinical trials, significantly reducing frequency of monthly migraine days over Weeks 1‒12. The objective of this analysis was to...

    Authors: Rami Apelian, Lee Boyle, Joe Hirman and Divya Asher
    Citation: The Journal of Headache and Pain 2022 23:48
  27. According to the Global Burden of Disease (GBD) study, headache disorders are among the most prevalent and disabling conditions worldwide. GBD builds on epidemiological studies (published and unpublished) whic...

    Authors: Lars Jacob Stovner, Knut Hagen, Mattias Linde and Timothy J. Steiner
    Citation: The Journal of Headache and Pain 2022 23:34
  28. The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of mig...

    Authors: Maurice T. Driessen, Joshua M. Cohen, Oscar Patterson-Lomba, Stephen F. Thompson, Michael Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu and Rajeev Ayyagari
    Citation: The Journal of Headache and Pain 2022 23:47
  29. Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs). Real-life studies are needed to explor...

    Authors: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi and Fabrizio Vernieri
    Citation: The Journal of Headache and Pain 2022 23:46

    The Correction to this article has been published in The Journal of Headache and Pain 2022 23:64

    The Correction to this article has been published in The Journal of Headache and Pain 2022 23:51

  30. Resting-state EEG microstates are thought to reflect brief activations of several interacting components of resting-state brain networks. Surprisingly, we still know little about the role of these microstates ...

    Authors: Yansong Li, Guoliang Chen, Jing Lv, Lei Hou, Zhao Dong, Rongfei Wang, Min Su and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2022 23:45
  31. Anomalous phantom visual perceptions coupled to an aversion and discomfort to some visual patterns (especially grating in mid-range spatial frequency) have been associated with the hyperresponsiveness in migra...

    Authors: Chun Yuen Fong, Wai Him Crystal Law, Johannes Jacobus Fahrenfort, Jason J. Braithwaite and Ali Mazaheri
    Citation: The Journal of Headache and Pain 2022 23:44
  32. Adenosine is a purinergic signaling molecule with a wide range of physiological functions including anti- and pronociceptive properties. Adenosine receptors are expressed in the trigeminovascular system, and a...

    Authors: Janu Thuraiaiyah, Lili Kokoti, Mohammad Al-Mahdi Al-Karagholi and Messoud Ashina
    Citation: The Journal of Headache and Pain 2022 23:43
  33. The incidence of migraines is higher among individuals with epilepsy than in healthy individuals, and these two diseases are thought to shared pathophysiological mechanisms. Excitation/inhibition imbalance pla...

    Authors: Yanjie Zhou, Lily Zhang, Yuyan Hao, Liu Yang, Shanghua Fan and Zheman Xiao
    Citation: The Journal of Headache and Pain 2022 23:42
  34. Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to reduce the risk of developing Coronavirus Disease 2019 (COVID-19). Despite the significant benefits in terms of reduced...

    Authors: Matteo Castaldo, Marta Waliszewska-Prosół, Maria Koutsokera, Micaela Robotti, Marcin Straburzyński, Loukia Apostolakopoulou, Mariarita Capizzi, Oneda Çibuku, Fidel Dominique Festin Ambat, Ilaria Frattale, Zukhra Gadzhieva, Erica Gallo, Anna Gryglas-Dworak, Gleni Halili, Asel Jusupova, Yana Koperskaya…
    Citation: The Journal of Headache and Pain 2022 23:41
  35. Migraine frequency increases after the cessation of successful preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs). In this study, we aimed to evaluate the course of migraine after treatment...

    Authors: Bianca Raffaelli, Maria Terhart, Jasper Mecklenburg, Lars Neeb, Lucas Hendrik Overeem, Anke Siebert, Maureen Steinicke and Uwe Reuter
    Citation: The Journal of Headache and Pain 2022 23:40
  36. Restless legs syndrome is a highly prevalent comorbidity of migraine; however, its genetic contributions remain unclear.

    Authors: Yun-Jin Jiang, Cathy Shen-Jang Fann, Jong-Ling Fuh, Ming-Yi Chung, Hui-Ying Huang, Kuo-Chang Chu, Yen-Feng Wang, Chia-Lin Hsu, Lung-Sen Kao, Shih-Pin Chen and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2022 23:39
  37. Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine preven...

    Authors: Raffaele Ornello, Carlo Baraldi, Simona Guerzoni, Giorgio Lambru, Anna P. Andreou, Bianca Raffaelli, Astrid Gendolla, Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Sabina Cevoli, Valentina Favoni, Fabrizio Vernieri, Claudia Altamura, Antonio Russo, Marcello Silvestro…
    Citation: The Journal of Headache and Pain 2022 23:38
  38. Cluster headache (CH) is a severe, highly disabling primary headache disorder. However, there is little research on CH-related disability, and most of it is based on non CH-specific questionnaires. The aim of ...

    Authors: Katharina Kamm, Andreas Straube and Ruth Ruscheweyh
    Citation: The Journal of Headache and Pain 2022 23:37
  39. Certain constituents in migraine food triggers and non-steroidal anti-inflammatory drugs (NSAIDs) inhibit sulfotransferases (SULTs) that detoxify drugs/chemicals and play role in the metabolism of neurotransmi...

    Authors: Doga Vuralli, Burak Arslan, Elif Topa, Andreia Lopes de Morais, Ozlem Gulbahar, Cenk Ayata and Hayrunnisa Bolay
    Citation: The Journal of Headache and Pain 2022 23:36
  40. Vestibular symptoms are frequently reported in patients with chronic migraine (CM). However, whether vestibular symptoms arise through overlapping neurobiology of migraine remains to be elucidated. The neurope...

    Authors: Ruimin Tian, Yun Zhang, Qi Pan, Yunfeng Wang, Qianwen Wen, Xiaoping Fan, Guangcheng Qin, Dunke Zhang, Lixue Chen, Yixin Zhang and Jiying Zhou
    Citation: The Journal of Headache and Pain 2022 23:35
  41. The paper from Steiner et al. suggests that an outcome measure expressed in time units may be an adequate method to assess the impact of headache disorders, regardless of diagnosis or health care setting, prov...

    Authors: Raquel Gil-Gouveia
    Citation: The Journal of Headache and Pain 2022 23:31
  42. Based on the current understanding of the role of neuropeptide signalling in migraine, we explored the therapeutic potential of a specific cannabinoid agonist. The aim of the present study was to examine the e...

    Authors: Isabella Mai Christiansen, Jacob C. A. Edvinsson, Philip V. Reducha, Lars Edvinsson and Kristian Agmund Haanes
    Citation: The Journal of Headache and Pain 2022 23:30
  43. A clinical ability to describe the response trajectory of patients receiving preventive migraine treatment could expedite and improve therapeutic management decisions. This post hoc analysis of the PROMISE-2 s...

    Authors: Dawn C. Buse, Paul K. Winner, Larry Charleston IV, Joe Hirman, Roger Cady and Thomas Brevig
    Citation: The Journal of Headache and Pain 2022 23:29
  44. Current pharmacologic prophylactic strategies for migraine have exhibited limited efficacy, with response rates as low as 40%–50%. In addition to the limited efficacy, the acceptability of those pharmacologic ...

    Authors: Yu-Chen Cheng, Bing-Yan Zeng, Chao-Ming Hung, Kuan-Pin Su, Yi-Cheng Wu, Yu-Kang Tu, Pao-Yen Lin, Brendon Stubbs, Andre F. Carvalho, Chih-Sung Liang, Tien-Yu Chen, Chih-Wei Hsu, Andre R. Brunoni, Mein-Woei Suen, Yow-Ling Shiue, Ping-Tao Tseng…
    Citation: The Journal of Headache and Pain 2022 23:28
  45. Post-traumatic headache (PTH) is a common symptom following mild traumatic brain injury (mTBI). Patients at risk to develop acute PTH (aPTH) and further persistent PTH (pPTH) need to be recognized.

    Authors: Yvonn Kraemer, Kaisa Mäki, Ivan Marinkovic, Taina Nybo, Harri Isokuortti, Antti Huovinen, Antti Korvenoja, Susanna Melkas and Hanna Harno
    Citation: The Journal of Headache and Pain 2022 23:27
  46. 5-Hydroxytryptamine (5-HT) receptors 1B, 1D and 1F have key roles in migraine pharmacotherapy. Selective agonists targeting these receptors, such as triptans and ditans, are effective in aborting acute migrain...

    Authors: Jacob C. A. Edvinsson, Aida Maddahi, Isabella M. Christiansen, Philip V. Reducha, Karin Warfvinge, Majid Sheykhzade, Lars Edvinsson and Kristian A. Haanes
    Citation: The Journal of Headache and Pain 2022 23:26
  47. Central sensitization is an important pathophysiological mechanism of chronic migraine (CM), and microglia activation in trigeminocervical complex (TCC) contributes to the development of central sensitization....

    Authors: Qi Pan, Yunfeng Wang, Ruimin Tian, Qianwen Wen, Guangcheng Qin, Dunke Zhang, Lixue Chen, Yixin Zhang and Jiying Zhou
    Citation: The Journal of Headache and Pain 2022 23:25